Please use this identifier to cite or link to this item:
Title: Liquid biopsies and minimal residual disease in myeloid malignancies
Authors: Allam, Sabine
Nasr, Kristina
Khalid, Farhan
Shah, Zunairah
Khan Suheb, Mahammed Ziauddin
Mulla, Sana
Vikash, Sindhu
Bou Zerdan, Maroun
Anwer, Faiz
Chaulagain, Chakra P
Affiliations: Faculty of Medicine 
Keywords: Acute myeloid leukemia
Acute myeloid leukemia (AML)
Artificial intelligence - AI
Blood biomarkers
Liquid biopsies
Minimal residual disease (MRD)
Myelodysplastic syndromes (MDS)
Myeloid malignancies
Issue Date: 2023-05
Publisher: National Library of Medicine
Part of: Frontiers in Oncology
Volume: 13
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies. Blood components then undergo molecular analysis by flow cytometry or sequencing techniques and can be used as a powerful tool for prognostic and predictive purposes in myeloid malignancies. There is evidence and more is evolving about the quantification and identification of cell-based and gene-based biomarkers in myeloid malignancies to monitor treatment response. MRD based acute myeloid leukemia protocol and clinical trials are currently incorporating LB testing and preliminary results are encouraging for potential widespread use in clinic in the near future. MRD monitoring using LBs are not standard in myelodysplastic syndrome (MDS) but this is an area of active investigation. In the future, LBs can replace more invasive techniques such as bone marrow biopsies. However, the routine clinical application of these markers continues to be an issue due to lack of standardization and limited number of studies investigating their specificities. Integrating artificial intelligence (AI) could help simplify the complex interpretation of molecular testing and reduce errors related to operator dependency. Though the field is rapidly evolving, the applicability of MRD testing using LB is mostly limited to research setting at this time due to the need for validation, regulatory approval, payer coverage, and cost issues. This review focuses on the types of biomarkers, most recent research exploring MRD and LB in myeloid malignancies, ongoing clinical trials, and the future of LB in the setting of AI.
ISSN: 2234-943X
DOI: 10.3389/fonc.2023.1164017
Open URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Jun 22, 2024

Record view(s)

checked on Jun 23, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.